(51) International Patent Classification 7 : A61K 51/04, C07D 243/24	A1	(11) International Publication Number: **WO 00/61195**
		(43) International Publication Date: 19 October 2000 (19.10.00)

(21) International Application Number: PCT/US00/10093

(22) International Filing Date: 14 April 2000 (14.04.00)

(30) Priority Data:
09/292,067   14 April 1999 (14.04.99)   US

(71) Applicants: DIATIDE, INC. [US/US]; 9 Delta Drive, Londonderry, NH 03053 (US). GENENTECH, INC. [US/US]; One DNA Way, South San Francisco, CA 94080 (US).

(72) Inventors: DEAN, Richard, T.; 43 Kind Road, Bedford, NH 03110 (US). LISTER-JAMES, John; 25 Old Stone Way, Bedford, NH 03110 (US). VENUTI, Michael, C.; 207 Montcalm Street, San Francisco, CA 94110 (US). SOMERS, Todd, C.; 1011 Buckland Avenue, San Carlos, CA 94070 (US).

(74) Agent: McDANIELS, Patricia, A.; Diatide, Inc., 9 Delta Drive, Londonderry, NH 03053 (US).

(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: BENZODIAZEPINE DERIVATIVES FOR IMAGING THROMBI

(57) Abstract

The invention provides compounds comprising glycoprotein IIb/IIIa receptor-binding benzodiazepine derivatives covalently linked to metal ion chelators. The compounds of the invention may be labeled with a radionuclide such as ^{99m}Tc and used to image thrombi.

BENZODIAZEPINE DERIVATIVES FOR IMAGING THROMBI

5   The present invention relates to the field of diagnostic imaging of thrombosis.
More particularly, the invention relates to pharmaceutical compositions for imaging
thrombi.

BACKGROUND OF THE INVENTION

10   Thrombi are blood clots which form within the cardiovascular system.
Formation of thrombi, *i.e.*, thrombosis, may cause local obstruction of blood vessels, for
example in veins, arteries, or capillaries. Venous thrombi usually form in lower limbs
and may produce acute symptoms by causing inflammation of the vessel wall or
obstruction of the vein. Pieces of venous thrombi may also circulate through the
15 cardiovascular system to form a plug, or embolus, at a distant site such as the lung.
Arterial thrombi are commonly associated with vascular disease such as atherosclerosis
and may produce tissue ischemia (local anemia) by obstructing blood flow or by
embolizing into capillaries. Thrombi may also form in the heart, for example, on
inflamed or damaged valves, on tissue adjacent to myocardial infarcts, within injured
20 chambers, or on prosthetic valves.

While all thrombi contain the protein fibrin and blood cells, the proportions of
particular blood cells present and of fibrin/blood cell may differ, for example, because of
the blood flow at the site of thrombus formation and thrombus age. Arterial thrombi
which form at sites of high blood flow contain platelet aggregates bound together by thin
25 fibrin strands. Venous thrombi form in areas of stagnant blood flow and contain red
blood cells with interspersed fibrin and fewer platelets. Thrombi which form under
conditions of slow to moderate flow contain a mixture of red cells, platelets, and fibrin.
Leukocytes, the white blood cells, migrate to and become incorporated into thrombi as
they age. In addition, aggregated platelets in aging thrombi lyse and are replaced by
30 fibrin.

Accurate detection of the various kinds of thrombi is necessary to choose, to
optimize and to monitor treatment, which may differ by virtue of the location and nature

of the thrombus. Recently, ACUTECT™, a kit for making the ^{99m}Tc-radiolabeled peptide, apcitide, was approved for sale in the US as a radiopharmaceutical product for imaging acute deep vein thrombosis (DVT). The commercial availability of ACUTECT™ will significantly improve the accuracy of detection of acute DVT, and

5   consequently, treatment of such thrombi. However, no radiopharmaceutical has thus far been approved for detection of other kinds of thrombi, and the most accurate methods available for detection of other venous thrombi such as pulmonary emboli and of arterial thrombi are invasive. Additional non-invasive agents capable of detecting the various kinds of thrombi are needed.

10   ^{99m}Tc-radiolabeled apcitide binds to the GPIIb/IIIa receptor, the most abundant glycoprotein on the surface of platelets. The GPIIb/IIIa receptor is required for platelet aggregation and is a critical component of thrombus formation, functioning as the receptor for the adhesive proteins fibrinogen (the precursor of fibrin), fibronectin, von Willebrand factor, and vitronectin. The interaction between GPIIb/IIIa and its

15   natural ligands is mediated by the tripeptide sequence arginine–glycine–aspartic acid (RGD). Apcitide contains the tripeptide —L-[S-(3-aminopropyl)cysteine]–glycine–aspartic acid—, which is believed to interact with GPIIb/IIIa.

U.S.Pat.No. 5,645,815 discloses that high quality thrombus imaging agents comprise GPIIb/IIIa receptor binding compounds which are capable of inhibiting

20   platelet aggregation with an IC_{50} less than about 0.3 µM. U.S.Pat.No. 5,830,856 discloses that such imaging agents may comprise GPIIb/IIIa receptor binding compounds which are capable of inhibiting platelet aggregation with an IC_{50} less than about 1.0 µM.

One class of GPIIb/IIIa binding platelet aggregation inhibitors, disclosed in

25   U.S.Pat.Nos. 5,403,836; 5,493,020; 5,565,449; 5,663,166; 5,674,863; 5,674,865; 5,705,890; and 5,716,951, are substituted benzodiazepinediones. The benzodiazepinedione scaffold approximates the "cupped" configuration of the RGD tripeptide, which correlates with platelet aggregation inhibitory activity. U.S.Pat.Nos. 5,403,836; 5,493,020; 5,565,449; 5,663,166; 5,674,863; 5,674,865; 5,705,890; and

30   5,716,951 describe several large classes of benzodiazepinedione derivatives, including derivatives of the general formula:

where R^1, R^2, and R^4 are each independently H or a reactive group; R^3 and R^5 are each independently H, alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; D is hydrogen, phenyl, or lower alkyl; L^1 is a linking moiety; and Q^1 is a positively charged nitrogen-containing moiety. The substituted benzodiazepinediones of U.S.Pat.Nos. 5,403,836; 5,493,020; 5,565,449; 5,663,166; 5,674,863; 5,674,865; 5,705,890; and 5,716,951 are exclusively described as therapeutic agents.

Ku, *et al.* (1993) *J. Am. Chem .Soc.* **115**, 8861-8862 describes design and synthesis of benzodiazepine derivatives useful as inhibitors of glycoprotein IIb/IIIa receptor mediated platelet aggregation. The 1,4-benzodiazepine derivatives of Ku, *et al.* are exclusively described as potential antithrombotic agents.

U.S.Pat.No. 4,656,026 describes spin-labeled benzodiazepines for magnetic resonance imaging of brain tissue. U.S.Pat.No. 4,777,169 discloses radioiodinated benzodiazepines used in radioimmunoassays to determine benzodiazepine levels in body fluids. U.S.Pat.No. 4,885,152 describes radioiodinated and radiobrominated benzodiazepine derivatives for detection of benzodiazepine receptors in cerebral diseases. U.S.Pat.No. 4,997,771 discloses ^{3}H-benzodiazepines used to assay benzodiazepine receptor binding activity. U.S.Pat.No. 5,096,695 discloses radioiodinated benzodiazepine derivatives for use as brain imaging agents. WO 95/12610 discloses N-alkyl peptide chelators which may be covalently linked to a variety of ligands, including benzodiazepines, for use in complexing rhenium or technetium ions. JP 5-310711 discloses N-substituted benzodiazepin-2-one derivatives for electron spin resonance imaging of benzodiazepine receptors in brain nerves to diagnose epilepsy, parkinsonism, cerebral ischemia and cerebral edema.

SUMMARY OF THE INVENTION

The present inventors have found that benzodiazepine derivatives may be employed as effective thrombus imaging agents.

In one embodiment, the invention provides a compound comprising a
5   glycoprotein IIb/IIIa receptor binding benzodiazepine derivative covalently linked to a metal ion chelator, wherein the compound retains substantial potency, as measured in a standard assay for inhibition of platelet aggregation.

In another embodiment, the invention provides a compound having a formula:

10

wherein M is a metal ion chelator.

In another embodiment, the invention provides a scintigraphic imaging agent comprising a γ-emitting radionuclide and a compound of the invention.

In another embodiment, the invention provides a complex of a γ-emitting
15   radionuclide and a compound of the invention.

In yet another embodiment, the invention provides a ^{99m}Tc chelate of a compound comprising a glycoprotein IIb/IIIa receptor binding benzodiazepine covalently linked to a metal ion chelating moiety, wherein the compound retains substantial potency for inhibition of human platelet aggregation, as measured in a
20   standard inhibition of platelet aggregation assay, when chelated to ^{99m}Tc, and wherein the chelate contains at least one sulfur ligand bound to ^{99m}Tc.

In another embodiment, the invention provides a method of detecting a thrombus in a mammalian body, comprising the steps of administering an effective diagnostic amount of the scintigraphic imaging agent or complex of the invention to
25   the body and detecting radiation localized at the thrombus.

DETAILED DESCRIPTION OF THE INVENTION

The patent and scientific literature referenced herein establish the knowledge

5   available to those with skill in the art. The issued U.S. patents and allowed

applications are hereby incorporated by reference.

The compounds of the invention comprise a glycoprotein IIb/IIIa receptor-

binding benzodiazepine moiety and a metal ion chelating moiety. In accordance with

the invention, the terms "benzodiazepine derivative" or "benzodiazepine moiety" are

10   interchangeable and are defined as including any molecule comprising the

benzodiazepine nucleus, *i.e.*, a seven-membered ring fused to an aromatic six-

membered ring. The compounds of the invention may comprise any benzodiazepine

moiety, so long as the compound retains substantial potency, as measured by the

inhibitory concentration at 50% (IC_{50}) of the compound for human platelet

15   aggregation in a standardized assay of inhibition of platelet aggregation, such as the

assay set forth in Zucker, *Methods in Enzymology* (1989) **169**, 117-133. As defined

herein, "substantial potency" is defined as: preferably, an IC_{50} for inhibition of human

platelet aggregation of less than about 1 µM; more preferably, an IC_{50} for inhibition

of human platelet aggregation of less than about 0.3 µM; and most preferably, an IC_{50}

20   for inhibition of human platelet aggregation of less than about 0.1 µM.

Preferably, the substituted 1,4-benzodiazepine derivatives disclosed in Ku *et*

al., supra, are used as the benzodiazepine moiety of the compounds of the invention,

so long as the substituted benzodiazepine can be further derivatized for covalent

attachment of a metal ion chelator without substantially affecting the platelet

25   aggregation inhibitory activity of the benzodiazepine. Similarly, any of the substituted

benzodiazepinediones disclosed in U.S.Pat.Nos. 5,403,836; 5,493,020; 5,565,449;

5,663,166; 5,674,863; 5,674,865; 5,705,890; and 5,716,951 is employed as the

benzodiazepine moiety of the compounds of the present invention, so long as the

substituted benzodiazepinedione can be further derivatized for covalent attachment of

30   a metal ion chelator without substantially affecting the platelet aggregation inhibitory

activity of the benzodiazepinedione. More preferably, the substituted 1,4-

benzodiazepine-2,5-diones disclosed and claimed in U.S.Pat.No. 5,663,166, are used

as glycoprotein IIb/IIIa binding moieties in the compounds of the invention. Most

preferably, substituted 1,4-benzodiazepine-2,5-diones corresponding to the formulae set forth below are used as glycoprotein IIb/IIIa binding moieties in the compounds of the invention.

In one embodiment, the invention provides a compound having a formula:

5

where R^1 is C_1-C_8 lower alkyl, R^2, R^3, R^4, R^5, and R^6 are each independently H, C_1-C_8 lower alkyl, substituted C_1-C_8 alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

10   As defined herein, "substituted C_1-C_8 alkyl" means an alkyl of the designated length substituted with a hydroxyl group, an ether, a thioether, a C_1-C_8 branched hydrocarbon, a C_1-C_8 straight chain hydrocarbon, an amine, a primary alkylamine, a secondary alkylamine, a primary arylamine, a secondary arylamine, a primary alkylsilicate, a secondary alklysilicate, a tertiary alkylsilicate, and the like. In

15   accordance with the invention, "aryl" may be saturated or unsaturated and may optionally be a heterocycle. A "substituted aryl" of the invention means an aryl which may optionally be a heterocycle and which is substituted at one or more positions with a hydroxyl group, an ether, a thioether, a C_1-C_8 branched hydrocarbon, a C_1-C_8 straight chain hydrocarbon, an amine, a primary alkylamine, a secondary

20   alkylamine, a primary arylamine, a secondary arylamine, a nitro group, a halogen, a sulfonic acid, an alkylsulfonyl, a sulfonamide, and the like.

In another embodiment, the invention provides a compound having a formula:

where R^2 is C_1-C_8 lower alkyl, R^1, R^3, R^4, R^5, and R^6 are each independently H, C_1-C_8 lower alkyl, substituted C_1-C_8 alkyl, aryl, substituted aryl, or a combination thereof;

5   L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

In another embodiment, the invention provides a compound having a formula:

where R^3 is C_1-C_8 lower alkyl; R^1, R^2, R^4, R^5, and R^6 are each independently H, C_1-C_8

10   lower alkyl, substituted C_1-C_8 alkyl, aryl, substituted aryl, or a combination thereof;

L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

In another embodiment, the invention provides a compound having a formula:

where R^4 is C_1-C_8 lower alkyl; R^1, R^2, R^3, R^5, and R^6 are each independently H, C_1-C_8 lower alkyl, substituted C_1-C_8 alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

5   In another embodiment, the invention provides a compound having a formula:

where R^5 is C_1-C_8 lower alkyl; R^1, R^2, R^3, R^4, and R^6 are each independently H, C_1-C_8 lower alkyl, substituted C_1-C_8 alkyl, aryl, substituted aryl, or a combination thereof;

10 L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

In another embodiment, the invention provides a compound having a formula:

where R^6 is C_1-C_8 lower alkyl; R^1, R^2, R^3, R^4, and R^5 are each independently H, C_1-C_8

15 lower alkyl, substituted C_1-C_8 alkyl, aryl, substituted aryl, or a combination thereof;

L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

In each of the formulae set forth above, linking moiety L^1 is a bivalent radical containing from about 3 to about 9 methylene groups, or L^1 may be a bivalent radical

20 having a length equivalent to from about 3 to about 9 methylene groups. Preferably, L^1 has a length equivalent to from about 4 to about 6 methylene groups. More preferably, L^1 has a length equivalent to about 5 methylene groups. L^1 preferably

contains one or more sp^2 or sp atoms and thus is constrained. In accordance with the
invention, L^1 may contain one or more alkene, alkyne, aryl, heterocycle groups, or a
functional group or groups containing N, O, or S. Preferably, L^1 comprises a ketone,
sulfoxide, secondary amine, amide, ureido, carbamate, sulfonamide, or sulfone. More
5   preferably, L^1 comprises a thioether. Most preferably, L^1 comprises an ether, in
particular, an alkylether such as a methylether.

Positively charged moiety Q contains one or more nitrogen atoms and has a
pK_b sufficiently high that said atoms are at least 10% positively charged at
physiological pH. In accordance with the invention, Q may comprise one or more
10   primary, secondary, tertiary, or quaternary amines or imines either isolated or
conjugated with other nitrogen atoms. Alternatively, Q may be a saturated or
unsaturated (including aromatic) heterocyclic group, provided that said group bears a
positive charge at physiological pH.

In accordance with the invention Q may be selected from but is not limited to such
15   groups as: amino, imino, amidino, aminomethyleneimino, aminomethyleneamino,
iminomethylamino, guanidino, N^G-aminoguanidino, alkylamino, dialkylamino,
trialkylamino, alkylideneamino, pyranyl, pyrroyl, imidazolyl, pyrazolyl, pyridyl,
pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, 1H-
indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl,
20   naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl,
carbazolyl, b-carbolinyl, phenanthridinyl, acridinyl, phenanthrolinyl, phenazinyl,
phenarsazinyl, phenothiazinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl,
pyrazolinyl, piperidyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl,
1,3-diazacyclohex-4-ene, and multiples thereof. Optionally, any of the nitrogen-
25   containing heterocycles set forth above may be substituted with amino, imino,
amidino, aminomethyleneamino, iminomethylamino, guanidino, N^G-amino-guanidine,
alkylamino, dialkylamino, trialkylamino, or alkylidene-amino groups. Preferably, Q
is a amidino or substituted amidino group.

Methods for making substituted glycoprotein IIb/IIIa receptor binding
30   benzodiazepinediones are disclosed in U.S.Pat.Nos. 5,403,836; 5,493,020; 5,565,449;
5,663,166; 5,674,863; 5,674,865; 5,705,890; and 5,716,951 and in Example 1 below.

Methods for making substituted glycoprotein IIb/IIIa receptor binding benzodiazepines are disclosed in Ku *et al., supra.*

The compounds of the invention may comprise any metal ion chelator. The metal ion chelator may be covalently linked to the substituted benzodiazepine at any
5   position of the benzodiazepine scaffold, so long as the presence of the chelator does not substantially interfere with the compound's ability to bind to the glycoprotein IIb/IIIa receptor. By "substantially interfere" is meant that the compound retains some potency for inhibition of human platelet aggregation, as defined above.

For example, the compounds of the invention may comprise a metal ion chelator
10   having a formula:

$$C(pgp)^S\text{-}(aa)\text{-}C(pgp)^S$$

where $(pgp)^S$ is hydrogen or a thiol protecting group and (aa) is any α- or β-amino acid not comprising a thiol group. In a preferred embodiment, the amino acid is glycine. Methods for making such a metal ion chelator are set forth in U.S.Pat.Nos. 5,654,272;
15   5,681,541; 5,788,960; and 5,811,394.

Alternatively, the compound of the invention may comprise a metal ion chelator of capable of forming an electrically neutral complex with the metal ion, as set forth in U.S.Pat.Nos. 5,720,934; 5,776,428; and 5,780,007; in allowed USSNs 08/467,791, 08/468,964; and 08/170,299; and in USSN 07/871,282. Such chelators
20   include but are not limited to:

wherein   X = H or a protecting group;

                (amino acid) = any amino acid;

25

wherein   X = H or a protecting group;

(amino acid) = any amino acid;

$$
\begin{array}{ccc}
 & \diagup (CR_2)_n \diagdown & \\
NH & & N\text{-}A\text{-}CO\text{-}benzodiazepine \\
| & & | \\
(CR_2)_m & & (CR_2)_p \\
| & & | \\
S\text{-}(pgp)^S & & S\text{-}(pgp)^S
\end{array}
$$

wherein each R can be independently H, CH_3 or C_2H_5; each $(pgp)^S$ can be independently a thiol protecting group or H; m, n and p are independently 2 or 3; A is linear C_1-C_8 alkyl, substituted linear C_1-C_8 alkyl, cyclic C_3-C_8 alkyl, substituted cyclic C_3-C_8 alkyl, aryl, substituted aryl, or a combination thereof; and X is benzodiazepine; and

$$
\begin{array}{ccc}
 & \diagup (CR_2)_n \diagdown & \\
NH & & N\text{-}A\text{-}CH(V)NHR' \\
| & & | \\
(CR_2)_m & & (CR_2)_p \\
| & & | \\
S\text{-}(pgp)^S & & S\text{-}(pgp)^S
\end{array}
$$

wherein each R is independently H, CH_3 or C_2H_5; m, n and p are independently 2 or 3; A is linear C_1-C_8 alkyl, substituted linear C_1-C_8 alkyl, cyclic C_3-C_8 alkyl, substituted cyclic C_3-C_8 alkyl, aryl, substituted aryl, or a combination thereof; V is H or CO-benzodiazepine; R' is H or benzodiazepine; provided that when V is H, R' is benzodiazepine and when R' is H, V is CO-benzodiazepine. In accordance with the invention, the substituted derivatives in the bisamide, bisthiol formulae are defined as set forth above.

Alternatively, the compound of the invention may comprise a metal ion chelator having a formula selected from the group consisting of:

diethylenetriaminepentaacetic acid (DTPA);

a derivative of DTPA having a formula

$(HOOCCH_2)_2N(CR_2)(CR_2)N(CH_2COOH)(CR_2)(CR_2)N(CH_2COOH)_2$;

where each R is independently H, C_1 to C_4 alkyl, or aryl and one R is covalently linked to a bivalent linker;

ethylenediaminetetraacetic acid (EDTA);

a derivative of EDTA having a formula

$(HOOCCH_2)_2N(CR_2)(CR_2)N(CH_2COOH)_2$;

where each R is independently H, C_1 to C_4 alkyl, or aryl and one R is covalently linked to a bivalent linker;

1,4,7,10-tetraazacyclododecanetetraacetic acid and derivatives thereof;

a metal ion chelator having a formula:

where n is an integer that is 2 or 3 and where each R is independently H, C_1 to C_4 alkyl, or aryl and one R is covalently linked to the benzodiazepine derivative,

and desferrioxamine.

More preferably, the compounds of the invention comprise a monoamine, diamide, single thiol containing metal ion chelator such as those set forth in commonly assigned copending USSN 08/253,973. Exemplary of such metal ion chelators are chelators having the formulae:

and

wherein n, m and p are each integers that are independently 0 or 1; each R' is independently H, lower alkyl, C_2-C_4 hydroxyalkyl, or C_2-C_4 alkoxyalkyl, and each R is independently H or R'', where R'' is a substituted C_1-C_8 alkyl not comprising a thiol group, a unsubstituted C_1-C_8 alkyl, an unsubstituted phenyl, or a substituted phenyl not comprising a thiol group, and one R or R' is L^2, where L^2 is a bivalent linker moiety linking the metal chelator to the glycoprotein IIb/IIIa receptor-binding benzodiazepine and wherein when one R' is L^2, NR'_2 is an amine. In this embodiment, L^2 may be a C_1-C_6 linear alkyl group, a branched chain alkyl group, a cyclic alkyl group, a carboxylic ester, a carboxamide, a sulfonamide, an ether, a thioether, an amine, an alkene, an alkyne, a 1,2- linked, optionally substituted, benzene ring, a 1,3-linked, optionally substituted, benzene ring, a 1,4-linked, optionally substituted, benzene ring, or an amino acid, or a combination thereof. In this embodiment, R'' may be a C_1-C_6 linear alkyl group; a branched alkyl group; a cyclic alkyl group; a $-C_qOC_r-$, $-C_qNHC_r-$ or $-C_qSC_r-$ group, where q and r are integers each independently 1 to 5 wherein the sum of q + r is not greater than 6; $(C_1$-$C_6)$ alkyl-X, where X is a hydroxyl group, a substituted amine, a guanidine, an amidine, a substituted thiol group, or a carboxylic acid, ester, phosphate, or sulfate group; a phenyl group or a phenyl group substituted with a halogen, a hydroxyl group, a substituted amine, a guanidine group, an amidine group, a substituted thiol, an ether, a phosphate, a sulfate; an indole group; a C_1-C_6 heterocyclic group containing 1 to 3 nitrogen, oxygen or sulfur atoms, or a combination thereof. In accordance with the invention, the substituted derivatives in the monoamine, diamide, thiol-containing chelator formulae are defined as set forth above.

Most preferably, the compounds of the invention comprise a metal ion chelator comprising a single thiol-containing group of formula:

$$A-CZ(B)-\{C(R^aR^b)\}_n-X$$

wherein A is H, HOOC–, H_2NOC–, –NHOC–, –OOC–, R^e_2NOC–, or R^d; B is H, SH, –NHR^c, –N(R^c)– or R^d; Z is H or R^d; X is SH, –NHR^c, –N(R^c)– or R^d; R^a, R^b, R^c and R^d are independently H, straight chain C_1-C_8 alkyl, branched chain C_1-C_8 alkyl, or cyclic C_3-C_8 alkyl; n is 0, 1 or 2; R^e is C_1-C_4 alkyl, an amino acid, or a peptide comprising 2 to about 10 amino acids; and: (1) where B is –NHR^c or –N(R^c)–, X is SH and n is 1 or 2; (2) where X is –NHR^c or –N(R^c)–, B is SH and n is 1 or 2; (3) where B is H or R^d, A is HOOC–, H_2NOC–, –NHOC–, or –OOC–, X is SH and n is 0 or 1; (4) where A is H or

13

R^d, then where B is SH, X is $-NHR^c$ or $-N(R^c)-$ and where X is SH, B is $-NHR^c$ or $-N(R^c)-$ and n is 1 or 2; (5) where X is H or R^d, A is HOOC–, H_2NOC-, –NHOC–, or –OOC– and B is SH; (6) where Z is methyl, X is methyl, A is HOOC–, H_2NOC-, –NHOC–, or –OOC– and B is SH and n is 0; and (7) where B is SH, X is not SH and where X is SH, B is not SH.

In accordance with the invention, a metal ion chelator comprising a single thiol-containing group may have the formula:

$$R^1\text{-CO-(amino acid)}^1\text{-(amino acid)}^2\text{-}Z^1$$

wherein (amino acid)^1 and (amino acid)^2 are each independently any primary α- or β-amino acid that does not comprise a thiol group, Z^1 is selected from the group consisting of cysteine, homocysteine, isocysteine, penicillamine, 2-mercaptoethylamine, 2-mercaptopropylamine, 2-mercapto-2-methylpropylamine, and 3-mercaptopropylamine, and R^1 is lower (C^1-C^4) alkyl, or R^1–CO is an amino acid, a peptide, or (aa)-peptide;

wherein when Z^1 is cysteine, homocysteine, isocysteine or penicillamine, Z^1 comprises a carbonyl group covalently linked to a hydroxyl group, a NR^3R^4 group, wherein each of R^3 and R^4 are independently H, a bond, lower (C^1-C^4) alkyl, an amino acid or a peptide comprising from 2 to 10 amino acids; and

Alternatively, a metal ion chelator comprising a single thiol-containing group may have the formula:

$$Y\text{-(amino acid)}^2\text{-(amino acid)}^1\text{-}NHR^2$$

wherein (amino acid)^1 and (amino acid)^2 are each independently any primary α- or β-amino acid that does not comprise a thiol group Y is selected from the group consisting of cysteine, homocysteine, isocysteine, penicillamine, 2-mercaptoacetate, 2-mercaptopropionate, 2-mercapto-2-methylpropionate, 3-mercaptopropionate, and R^2 is H, a bond, lower (C^1-C^4) alkyl, and NHR^2 is an amino acid, a peptide, or (aa)-peptide;

wherein when Y is cysteine, homocysteine, isocysteine or penicillamine, Y comprises an amino group covalently linked to –H, an amino acid, a peptide, or (aa)-peptide.

Any naturally occurring, modified, substituted, or altered amino acid may be used in the single-thiol chelators of the invention. As used herein, the term " modified, substituted, or altered α- or β- amino acid" includes, without limitation, penicillamine (Pen); 6-aminocaproic acid (Aca); homolysine (Hly); L-{S-(3-aminopropyl)cysteine} (Apc); D-amino acids such as D-phenylalanine (F_D), D-tryptophan (W_D), D-tyrosine (Y_D),

14

and the like; L-(4-chlorophenyl)alanine (Cpa); 4-amino-tetrahydrothiopyran-4-carboxylic acid (Thp); 2-naphthylalanine (Nal); D-2-naphthylalanine (D-Nal); dipropylglycine (Dpg); norleucine (Nle); homocysteine (Hcy); homohomocysteine (Hhc); aminoisobutyric acid (Aib); 2-aminoindan-2-carboxylic acid (Ain); 4-amino-

5   cyclohexylalanine (Achxa); 4-aminomethyl-phenylalanine (Amf); S-(2-aminoethyl)cysteine (Aec); is O-(3-aminopropyl)serine (Aps); 2-aminobutyric acid (Abu); norvaline (Nva); 4-amidino-phenylalanine (Amp), 2-amino suberic acid (Asu), and the like. In accordance with the invention, the carboxyl terminal amino acids of the chelators of the invention may be in carboxylic acid form or in amidated form.

10   For example, suitable metal ion chelators may have any of the following formulae:

   (amino acid)^1-(amino acid)^2-cysteine-,

   (amino acid)^1-(amino acid)^2-isocysteine-,

   (amino acid)^1-(amino acid)^2-homocysteine-,

15   (amino acid)^1-(amino acid)^2-penicillamine-,

   (amino acid)^1-(amino acid)^2-2-mercaptoethylamine-,

   (amino acid)^1-(amino acid)^2-2-mercaptopropylamine-,

   (amino acid)^1-(amino acid)^2-2-mercapto-2-methylpropylamine-,

   (amino acid)^1-(amino acid)^2-3-mercaptopropylamine-,

20   wherein the chelator is attached to either a substituted benzodiazepine or a linker group *via* a covalent bond with the carboxyl terminus of the chelator or a side chain on one of the amino acid groups.

   Other suitable metal ion chelators include those selected from the group consisting of:

25   -cysteine-(amino acid)-(α,β- or β,γ-diamino acid);

   -isocysteine-(amino acid)-(α,β- or β,γ-diamino acid);

   -homocysteine-(amino acid)-(α,β- or β,γ-diamino acid);

   -penicillamine-(amino acid)-(α,β- or β,γ-diamino acid);

   2-mercaptoacetic acid-(amino acid)-(α,β- or β,γ-diamino acid);

30   2- or 3-mercaptopropionic acid-(amino acid)-(α,β- or β,γ-diamino acid);

   2-mercapto-2-methylpropionic acid-(amino acid)-(α,β- or β,γ-diamino acid);

wherein the metal ion chelator is attached to either a substituted benzodiazepine or a linker group *via* a covalent bond with the amino terminus of the chelator or a side chain on one of the amino acid groups.

For example, the compounds of the invention may include metal ion chelators

5   having a formula selected from the group consisting of: –Gly–Gly–Cys, –Gly–Gly–Cys.amide, Gly–Gly–Cys–, Cys–Gly–Gly–, –Gly–Gly–Gly–Cys (SEQ ID.NO:1), –Gly–Gly–Gly–Cys.amide (SEQ. ID.NO:1), Arg–Gly–Cys–, –(ε-Lys)–Gly–Cys–, –(δ-Orn)–Gly–Cys–, –(γ-Dab)–Gly–Cys–, and –(β-Dap)–Lys–Cys–, and the like. (In these formulae, it will be understood that ε-Lys represents a lysine residue in which the ε-

10   amino group, rather than the typical α-amino group, is covalently linked to the carboxyl group of the adjacent amino acid to form a peptide bond; δ-Orn represents an ornithine residue in which the δ-amino group, rather than the typical α-amino group, is covalently linked to the carboxyl group of the adjacent amino acid to form a peptide bond; γ-Dab represents a 2,4-diaminobutyric acid residue in which the γ-amino group is covalently

15   linked to the carboxyl group of the adjacent amino acid to form a peptide bond; and β-Dap represents a 1,3-diaminopropionic acid residue in which the β-amino group is covalently linked to the carboxyl group of the adjacent amino acid to form a peptide bond. Other abbreviations for amino acids are conventional. The designation "Cys.amide" represents the amidated form of the residue cysteine.)

20   Methods for making metal ion chelators of the most preferred embodiment are set forth in U.S.Pat.Nos. 5,443,815; 5,807,537; 5,814,297; and 5,866,097 and in USSNs 08/236,402; 08/253,678; 08/253,973; and 08/582,134.

Those of skill will recognize that most metal ions may be chelated to the above-mentioned metal ion chelators. Any metal ion capable of generating a signal label may

25   be chelated to the benzodiazepine derivative compound of the invention, thus forming a metal ion complex with the compound of the invention. Suitable metal ions include radioactive metal ions, fluorescent metal ions, paramagnetic metal ions, heavy metals, rare earth ions suitable for use in computerized tomography, and the like. Radioactive metal ions or radionuclides are preferred. More preferably, γ-emitting radionuclides

30   such as ^{67}Cu, ^{68}Ga, ^{111}In, and ^{99m}Tc, are used in the methods of the invention. Most preferably, complexes formed between, ^{99m}Tc and the compounds of the invention are used to image thrombi.

The metal ion chelator associates with the metal ion to form a chelate, and the atoms of a chelator are commonly known as "ligands". In the chelating art, ligands are atoms capable of donating electrons to form the coordinate bonds of the chelate. In accordance with the invention, when the metal ion is ^{99m}Tc, the chelate is termed a

5   "^{99m}Tc-chelate". ^{99m}Tc is a thiophilic metal, and thus the ^{99m}Tc-chelates of the invention preferably contain at least one sulfur ligand bound via a coordinate covalent bond to the ^{99m}Tc.

Complexes and chelates of the invention may be formed using known methods. For example, a salt of ^{99m}Tc pertechnetate may be reacted with the compound

10   in the presence of a reducing agent such as dithionite ions, stannous ions or ferrous ions. In this method, the most preferred reducing agent is stannous chloride. Alternatively, complexes and chelates may be formed by ligand exchange, wherein the compound of the invention is reacted with a pre-formed labile complex of ^{99m}Tc and another compound known as a transfer ligand. In this process, any transfer ligand may be used,

15   for example, tartrate, citrate, gluconate, glucoheptonate, or mannitol.

Thrombus imaging agents produced using the compounds of the invention are preferably administered intravenously to a living mammal, as pharmaceutical compositions. The compound of the invention is formulated as a sterile, pyrogen-free, parenterally acceptable aqueous solution which may optionally be supplied in

20   lyophilized form and be reconstituted by the user.

The pharmaceutical composition of the invention comprise a compound of the invention in combination with a pharmaceutically acceptable diluent or a carrier such as species appropriate albumin. As used herein, a "pharmaceutically acceptable diluent or carrier" may include any and all solvents, dispersion media, antibacterial

25   and antifungal agents, isotonic agents, enzyme inhibitors, stabilizers, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. For example, Sodium Chloride Injection and Ringer's Injection are commonly used as diluents. The preparation of such parenterally acceptable solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the

30   art.

The compounds and compositions of the invention may be provided as components of kits which may include buffers, additional vials, instructions for use,

17

and the like. The kit of the invention comprises a sealed vial containing a predetermined quantity of the compound, and optionally, when the metal ion is technetium-99m, a reducing agent. An appropriate amount of a transfer ligand such as tartrate, citrate, gluconate, glucoheptonate or mannitol, for example, can also be included in the kit. The components of the kit may be in liquid, frozen or dry form. Preferably, kit components are provided in lyophilized form.

In accordance with the method of this invention, imaging agents produced from pharmaceutical compositions comprising the benzodiazepine derivative compounds of the invention are preferably administered intravenously in a single unit dose, either totally as a bolus or partly as a bolus followed by infusion over 1-2 hours.. The amount of solution to be injected at unit dosage is from about 0.01 mL to about 10 mL, containing about 0.01 mCi to about 100 mCi of radioactivity, preferably from about 1 mCi to about 20 mCi.. The amount of the compound in the unit dose may range from about 0.1 to about 10 mg/kg body weight, After intravenous administration, the thrombus site is monitored, for example, by radioimaging *in vivo*.

The following examples are shown by way of illustration and not by way of limitation.

EXAMPLE 1

Synthesis Of 1-[(carboxyglycyl-glycyl-glycyl-cysteinamide)methyl]-4-(2-carboxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione

Synthesis of an exemplary benzodiazepinedione imaging agent is set forth below.

A.   N-Boc-5-hydroxyanthranilic acid [1]

5-Hydroxyanthranilic acid (100 g, 0.65 mol) was transferred into a 5 liter 3-necked round bottom flask equipped with a mechanical stirrer. A solution of saturated sodium carbonate (1.5 liters) was added to the reaction flask with stirring. After carbon dioxide evolution had subsided, di-t-butyldicarbonate (156.8 g, 0.72 mol) in 1.5 liters of tetrahydrofuran (THF) was added to the reaction vessel which was stirred at a rate which insured complete mixing of the resulting biphasic mixture. The reaction mixture was stirred at room temperature for 24 hours at which time 1.0 liters of ethyl ether was added and the mixture transferred to a separatory funnel. The aqueous layer was extracted with an additional 1.0 liters of ethyl ether and brought to pH = 3.0 with 2 M H_3PO_4. Product was extracted from the aqueous solution with ethyl acetate (3 x 1.0 liters). The combined organics were washed with a saturated NaCl solution, dried over Na_2SO_4, filtered and concentrated *in vacuo* to yield N-Boc-5-hydroxyanthranilic acid (153 g, 92.5 % yield).

B.   N-Boc-5-benzyloxyanthranilic acid, benzyl ester [2]

Sodium hydride (95%, 36.2 g, 1.51 mol) was placed into a dry 5 liter 3-necked round bottom flask under an atmosphere of argon. Anhydrous dimethylformamide (DMF) (2.0 liters) was added via canula followed by the careful addition of N-Boc-5-hydroxyanthranilic acid (150 g, 0.59 mol). The reaction mixture was cooled with an ice/water bath and benzyl bromide (148 mL, 1.24 mol) was added via syringe keeping the reaction temperature below 50°C. After addition was complete, the reaction mixture was stirred at 45°C – 50°C for 6 hours. At this time additional benzyl bromide (35 mL, 0.29 mol) was added and the reaction continued at 45°C – 50°C for an additional 2 hours. Acetic acid (20 mL) was carefully added and the reaction

mixture was transferred to a round bottom flask and concentrated to a volume of approximately 400 mL. Ethyl acetate (1.0 liters) was added and the resulting solution was decanted from any solids present. The flask was rinsed with additional ethyl acetate (2 x 500 mL), decanting after each rinse. The combined organics were

5   washed with water (1.0 liter) and saturated NaCl (500 mL). The organics were filtered and concentrated *in vacuo* to yield crude N-Boc-5-benzyloxyanthranilic acid, benzyl ester as a reddish brown syrup. The crude product was transferred to boiling hexanes (3 liters) and refluxed an additional 10 minutes. The solution was filtered while still hot and allowed to cool for 48 hours to yield 72 g of product (28 % yield).

10

C.   **5-Benzyloxyanthranilic acid, benzyl ester, hydrochloride [3]**

N-Boc-5-benzyloxyanthranilic acid, benzyl ester (70 g, 161 mmol) was added to a 1.4 M HCl/ethyl acetate solution (prepared by the addition of methanol to acetyl chloride and subsequent dilution with ethyl acetate). The reaction mixture was stirred

15   at room temperature for 21 hours. After cooling to 0°C, the reaction was gently stirred for an additional 2 hours. The crystalline product was filtered off and washed with 50 ml of cold ethyl acetate. Trace solvents were removed under high vacuum to yield 5-benzyloxyanthranilic acid, benzyl ester, hydrochloride (53.4 g, 86 % yield).

20   D.   **N-(Carbo-t-butoxymethyl)-5-benzyloxyanthranilic acid, benzyl ester [4]**

A solution of saturated sodium bicarbonate (1.0 liter) was placed in a 4 liter Ehrlenmeyer flask along with 1.0 liter of ethyl acetate. The biphasic mixture was stirred at a rate that insured mixing and 5-benzyloxyanthranilic acid, benzyl ester, hydrochloride (50.0 g, 135 mmol) was added portionwise to the stirred mixture. After

25   addition was complete, the mixture was stirred an additional 15 minutes. The layers were partitioned in a separatory funnel and the aqueous layer was extracted with ethyl acetate (500 mL). The combined organics were dried over MgSO$_4$, filtered, and concentrated *in vacuo* to yield the free base, which was dissolved in anhydrous DMF (700 mL) under an atmosphere of argon. 2,6-lutidine (20.0 mL, 172 mmol) was

30   added to the solution followed by the addition of t-butyl bromoacetate (29.0 mL, 196 mmol). The reaction mixture was stirred at 70°C under an atmosphere of argon for 48 hours. The DMF was removed on a rotary evaporator under high vacuum and the

20

crude product residue was partitioned between ethyl acetate (1.0 liter) and water (500 mL). The organic layer was washed with saturated NaCl (250 mL) and dried over Na_2SO_4. The solution was filtered and concentrated *in vacuo* to yield crude product as a light brown solid. The product was recrystallized from 7% ethyl acetate/hexanes

5   to yield N-(carbo-t-butoxymethyl)-5-benzyloxyanthranilic acid, benzyl ester (46.4 g, 79 % yield).

E.   **N-(Carbo-t-butoxymethyl)-5-hydroxyanthranilic acid [5]**

N-(Carbo-t-butoxymethyl)-5-benzyloxyanthranilic acid, benzyl ester (45.0 g,

10   101 mmol) was dissolved in 1:1 THF/ethyl acetate (1200 mL) in a 2 liter round bottom flask. The atmosphere was flushed with argon and 10% Pd/C (4.0 g) was added. The reaction atmosphere was replaced with hydrogen gas (4 purge-fill cycles) and the reaction mixture stirred under a balloon of hydrogen for 23 hours. The atmosphere was replaced with argon and the reaction mixture filtered through a pad of

15   Celite, washing the Celite pad with methanol (250 mL). The solvents were removed *in vacuo* and the resulting yellow solid placed under high vacuum overnight to yield N-(carbo-t-butoxymethyl)-5-hydroxyanthranilic acid (27.1 g, 100% yield).

20   F.   **N-(Carbobenzyloxymethyl)-3-aminopropionic acid, ethyl ester [6]**

Ethyl acrylate (24.4 mL, 225 mmol) and glycine, benzyl ester, p-toluenesulfonate (50.0 g, 148 mmol) were combined in a 250 mL round bottom flask. With stirring, triethylamine (24.8 mL, 178 mmol) was added via syringe and the reaction mixture was stirred at room temperature for 22 hours. The reaction mixture

25   was partitioned between ethyl acetate (660 mL) and 10% aqueous Na_2CO_3 (300 mL). The organics were washed with water (100 mL) and saturated NaCl (100 mL). The organics were dried over $MgSO_4$, filtered and concentrated *in vacuo* followed by pumping under high vacuum to yield N-(carbobenzyloxymethyl)-3-aminopropionic acid, ethyl ester (39.3 g, 73% yield) as a yellow oil.

30

F.   **1-(Carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-hydroxy-3,4-dihydro-
1H-1,4-benzodiazepine-2,5-dione [7]**

N-(Carbo-t-butoxymethyl)-5-hydroxyanthranilic acid (26.7 g, 100 mmol) was

placed in a dry 2 liter round bottom flask. The reaction atmosphere was flushed with

5   argon and N-(carbobenzyloxymethyl)-3-aminopropionic acid, ethyl ester (29.0 g, 109

mmol) in anhydrous DMF (500 mL) was added, followed by the addition of O-(7-

azabenzotriaol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU

reagent, 39.9 g, 105 mmol). Triethylamine (42.0 mL, 301 mmol) was added and the

reaction mixture was stirred at room temperature under a balloon of argon for 16

10   hours. The DMF was removed *in vacuo* on a rotary evaporator and the residue

partitioned between ethyl acetate (1.0 liter) and saturated NaHCO₃ (500 mL). The

organics were washed with water (500 mL), saturated NaCl (100 mL) and dried over

MgSO₄. The organics were filtered, the volatiles removed *in vacuo* on a rotary

evaporator and the residual oil pumped on under high vacuum to yield an oil. This oil

15   was taken up in 9:3 ethyl acetate/methanol (1200 mL) and placed under an

atmosphere of argon gas. 10% Pd/C (4.0 g) was added and the reaction atmosphere

replaced with hydrogen gas (4 purge-fills). The reaction mixture was stirred under a

balloon of hydrogen for 45 hours. The reaction atmosphere was replaced with argon

and the suspension filtered through a pad of Celite, which was washed with an

20   additional 300 mL of methanol. The volatiles were removed *in vacuo* and the residue

was taken up in a minimum of dichloromethane and chromatographed on silica gel,

eluting the column with 1:1 ethyl acetate/hexanes. Fractions containing pure product

(Rf = 0.17 in 1:1 ethyl acetate/hexanes) were combined and the solvents removed *in*

vacuo to yield 1-(carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-hydroxy-3,4-

25   dihydro-1H-1,4-benzodiazepine-2,5-dione as a white solid (20.2 g, 50% yield).

G.   **1-(Carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-
cyanophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione [8]**

1-(Carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-hydroxy-3,4-dihydro-1H-

30   1,4-benzodiazepine-2,5-dione (19.5 g, 48 mmol), α-bromo-*p*-tolunitrile (11.3 g, 58

mmol), and potassium carbonate (9.0 g, 65 mmol) were combined in a round bottom

flask. Anhydrous DMF (300 mL) was added and the reaction mixture was stirred at

40°C for 4 days. The reaction mixture was filtered and the filtrate was concentrated *in*

vacuo on a rotary evaporator. The residue was partitioned between ethyl acetate (500 mL) and water (100 mL). The organics were washed with saturated NaCl (50 mL) and dried over Na₂SO₄. The volatiles were removed *in vacuo* on a rotary evaporator and the residue was chromatographed on silica gel, eluting the column with 5:6 ethyl

5   acetate/hexanes. Fractions containing pure product (Rf = 0.17, 5:6 ethyl acetate/hexanes) were combined and the solvents removed *in vacuo* on a rotary evaporator to yield 1-(carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-cyanophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione (20.7 g, 83% yield).

10

H.   **1-(Carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, acetate [9]**

        1-(Carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-cyanophenyl)methyl]-

15   3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione (16.0 g, 31 mmol) was placed in a dry 3-necked flask equipped with an inlet tube for gas dispersion and an outlet tube connected to a trap containing 1:1 2M NaOH/Clorox bleach. The flask was flushed with argon gas and anhydrous pyridine (90 mL) was added followed by the addition of triethylamine (70 mL). The resulting solution was saturated with hydrogen sulfide

20   gas. The inlet and outlet tubes were removed and the reaction mixture was heated at 55°C – 60°C for 21 hours. The reaction mixture was purged with argon and the volatiles removed *in vacuo* on a rotary evaporator. The residue was taken up in 5:4 dichloromethane/toluene (450 mL) and this was also removed *in vacuo* on a rotary evaporator. The treatment with dichloromethane/toluene was repeated once more.

25   The residue was taken up in acetone (300 mL) and iodomethane (5.2 mL, 84 mmol) was added via syringe. The reaction mixture was stirred and heated at 60°C – 65°C for 5.5 hours. The reaction mixture was cooled and the volatiles removed *in vacuo* on a rotary evaporator. The residue was taken up in anhydrous methanol (200 mL) under and atmosphere of argon and ammonium acetate (9.25 g, 120 mmol) was added. The

30   reaction mixture was stirred at room temperature under an atmosphere of argon for 21 hours. The volatiles removed *in vacuo* on a rotary evaporator and the residue was taken up in acetonitrile (200 mL) and filtered through a sintered glass funnel. The reaction vessel was rinsed with additional acetonitrile (100 mL) which was also

23

filtered through the sintered glass funnel. The filtrate was concentrated *in vacuo* on a

rotary evaporator and the residue pumped on under high vacuum to yield 1-(carbo-t-

butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-

1,4-benzodiazepine-2,5-dione, acetate (18.2 g, 99% yield).

5

    I.   **1-(Carboxymethyl)-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, hydrochloride [10]**

        1-(carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-

amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, acetate (17.7

10   g, 30 mmol) was placed in a dry round bottom flask and 4M HCl/dioxane was added

via syringe. The reaction mixture was stirred at room temperature for 1.5 hours and

then added dropwise to a stirred solution of anhydrous ethyl ether (1.0 liter). After

addition was complete, the resulting suspension was stirred an additional 15 minutes

and filtered under a blanket of argon gas. The collected solid was washed with

15   anhydrous ethyl ether, transferred to a round bottom flask, and dried under high

vacuum to yield 1-(carboxymethyl)-4-(2-carboethoxyethyl)-7-[(4-

amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, hydrochloride

as a white solid (14.2 g, 93 % yield). ^{1}H NMR (CD$_3$OD): 1.25 ppm, (t, 3H); 2.70

ppm, (m, 2H); 3.70 ppm – 4.21 ppm, (m, 4H); 4.12 (q, 2H); 4.50 ppm, (s, 2H); 5.39

20   ppm, (s, 2H); 7.20 ppm – 7.40 ppm (m, 3H); 7.71 ppm (d, 2H); 7.83 ppm (d, 2H).

    J.   **Fmoc-Glycyl-glycyl-glycyl-S-Tritylcysteinyl-Rink amide resin [11]**

        Fmoc-Rink amide resin (12.5 g, 0.66 mmol/g, 8.25 mmol) was sequentially

coupled to N-Fmoc-S-tritylcysteine, Fmoc-glycine, Fmoc-glycine, Fmoc-glycine, and

25   Fmoc-glycine using the following solid-phase peptide synthesis protocol: The N-

terminal Fmoc group was removed by treatment of the resin with 20%

piperidine/DMF (2 times, 5 min. then 15 min.). The resin was washed with DMF (4 x

1 min.). The resulting resin-supported N-terminal free amine was suspended in DMF

and reacted with N-Fmoc-S-tritylcysteine (13.7 g, 23.4 mmol), which was

30   preactivated with a 0.45M solution of 1:1 2-(1H-benzotriazole-1-yl)-1,1,3,3,-

tetramethyluronium hexafluorophosphate/N-hydroxybenzotriazole (HBTU/HOBt) in

DMF (52 mL, 23.4 mmol) and diisopropylethylamine (8.3 mL, 47.6 mmol). The

reaction time was for 2 hours. The resin was washed with DMF (3 times),

24

dichloromethane (3 times), and DMF (3 times). Fmoc-glycine (7.0 g, 23.5 mmol) was

similarly reacted with the resin supported peptide in three sequential procedures to

produce Fmoc-glycyl-glycyl-glycyl-S-tritylcysteinyl-Rink amide resin. The resin was

washed with dichloromethane (3 times) and dried in vacuo. Substitution analysis on a

5   small portion of resin indicated that resin substitution was 0.13 mmol/g.

K.   1-[(Carboxyglycyl-glycyl-glycyl-S-tritylcysteinamide)methyl]-4-(2-
         carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-
         benzodiazepine-2,5-dione, trifluoroacetate [12]

10   Fmoc-glycyl-glycyl-glycyl-S-tritylcysteinyl-Rink amide resin (53.4 g, 6.94

mmol) was treated (2 times) with 20% piperidine/DMF (75 mL, 5 min. then 15 min.)

and washed with DMF (4 times). Separately, 1-(carboxymethyl)-4-(2-

carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-

2,5-dione, hydrochloride (5.9 g, 11.36 mmol) was placed in a dry round bottom flask

15   under an atmosphere of argon and dissolved in anhydrous DMF (75 mL). This

solution was stirred and cooled to 0°C and treated with 4-methylmorpholine (1.01 mL,

9.2 mmol) followed by the dropwise addition of isobutyl chloroformate (1.13 mL, 8.7

mmol). After addition was complete, the solution was stirred at 0°C for an additional

5 minutes and added to the resin-supported peptide free amine that was generated

20   above. The resin suspension was agitated for 3 hours. The resin was washed with

DMF (6 times) and dichloromethane (3 times). The resin was treated three times with

trifluoroacetic acid (40 mL) for 10 minutes, each time draining the deprotection

mixture into a round bottom flask. The resin was washed twice with dichloromethane

(75 mL). The dichloromethane washes were combined with the trifluoroacetic acid

25   deprotection mixtures and the volatiles removed in vacuo on a rotary evaporator. The

residue was treated with anhydrous chloroform several times, each time removing the

chloroform in vacuo on a rotary evaporator. This is done until the orange/yellow

color of the residue disappears, indicating reattachment of the trityl group to the

cysteine sulfhydryl. The crude product was pumped on under high vacuum to yield 1-

30   [(carboxyglycyl-glycyl-glycyl-S-tritylcysteinamide)methyl]-4-(2-carboethoxyethyl)-

7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione,

trifluoroacetate (8.4 g). The product was purified by reversed-phase C18 HPLC. The

column was loaded with a DMF solution of crude product (70 mg/mL) and eluted

25

with a linear gradient of 0.1% TFA in 90% acetonitrile/water (solvent B) and 0.1%

TFA in water (solvent A). The gradient was from 20% B/A to 45% B/A over 40

minutes. Fractions were analyzed by reversed-phase C18 HPLC and fractions

containing pure product were combined and lyophilized to yield 1-[(carboxyglycyl-

5   glycyl-glycyl-S-tritylcysteinamide)methyl]-4-(2-carboethoxyethyl)-7-[(4-

amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione,

trifluoroacetate as a white powder (2.41 g, 2.17 mmol, 31 % yield). Electrospray

mass spectral analysis indicated a molecular ion peak (M + H$^+$) of 998 (theoretical for

$C_{52}H_{56}N_9O_{10}S_1$ is 998.4).

10

L.   **1-[(Carboxyglycyl-glycyl-glycyl-cysteinamide)methyl]-4-(2-carboxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, trifluoroacetate [13]**

1-[(carboxyglycyl-glycyl-glycyl-S-tritylcysteinamide)methyl]-4-(2-

15   carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-

2,5-dione, trifluoroacetate (2.38 g, 2.14 mmol) was placed in a round bottom flask and

dissolved in methanol (100 mL). The stirred solution was treated with an aqueous

solution of 1.0 M lithium hydroxide (8.7 mL, 8.7 mmol) at room temperature for 20

hours. Trifluoroacetic acid (0.67 mL, 8.7 mmol) was added to quench the reaction

20   and the volatiles were removed *in vacuo* on a rotary evaporator. The residue was

treated with a 91:4:5 mixture of trifluoroacetic acid/triethylsilane/water (100 mL) for

45 minutes. The volatiles were removed *in vacuo* on a rotary evaporator. The residue

was dissolved in 0.1% TFA in 90% acetonitrile/water (20 mL) and the stirred solution

was diluted with 0.1% TFA in water (200 mL). The resulting precipitate was filtered

25   off through a pad of Celite, which was washed with additional 0.1% TFA in water

(100 mL). The combined filtrates were purified (in portions) by preparative reversed-

phase C18 HPLC. The column was eluted with a linear gradient of 100% A to 15%

B/A over 40 minutes (0.1% TFA in water is solvent A and 0.1% TFA in 90%

acetonitrile/water is solvent B). Fractions were analyzed by reversed-phase C18

30   HPLC and fractions containing pure product were combined and lyophilized to yield

1-[(carboxyglycyl-glycyl-glycyl-cysteinamide)methyl]-4-(2-carboxyethyl)-7-[(4-

amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione,

trifluoroacetate as a white powder (1.08 g, 12.4 mmol, 58 % yield).

EXAMPLE 2

Placebo Vial Method for Radiolabeling with Technetium-99m

5   Approximately 100 μg of the benzodiazepine derivative compound of

Example 1 as 100 μL of a 1 mg/mL TFA salt solution dissolved in 0.9% saline was

added to a "placebo vial", containing lyophilized 5 mg sodium glucoheptanate

dihydrate, 50 μg stannous chloride dihydrate, and 100 μg sodium edetate dihydrate.

The vial was then reconstituted with ^{99m}Tc-sodium pertechnetate (30 to 50 mCi) and

10   saline such that the total volume was 1.1 mL. Following reconstitution, the vials

were incubated at room temperature for 30 minutes.

          The purity of the ^{99m}Tc-labeled benzodiazepinedione derivative was

determined by reverse-phase analytical HPLC using the following conditions: a

Waters Delta Pak C18, 5 μ, 3.9 mm x 150 mm analytical column was loaded with

15   each radiolabeled peptide, and the peptides eluted at a solvent flow rate equal to 1.2

mL/min. Gradient elution was performed using a linear gradient of 12-25% Solvent

B/Solvent A (Solvent A is 0.1% (v/v) trifluoroacetic acid (TFA) in water and Solvent

B is 0.1% (v/v) TFA in 90/10 (v/v) acetonitrile/water) over 20 minutes; followed by a

linear gradient of 25-100% Solvent B/Solvent A over four minutes and 100% Solvent

20   B/Solvent A for three minutes (Method 1).

          Radioactive components were detected in the HPLC method using an in-line

radiometric detector linked to a computerized data collection and analysis system

(Waters Millenium). ^{99m}Tc-glucoheptate, ^{99m}Tc-edetate, and ^{99m}Tc-sodium

pertechnetate elute between one and four minutes under these conditions, whereas the

25   ^{99m}Tc-labeled benzodiazepinedione derivatives eluted after a much greater time. The

radiochemical purity (as determined by the % area of the main ^{99m}Tc product peaks)

was ≥ 90%.

          The purity of the ^{99m}Tc-labeled benzodiazepinedione derivative was also

determined by TLC quality control analysis. The radiolabeled peptide samples were

30   spotted at the origin of each of two Gelman ITLC-SG strips. One strip each was

developed in saturated saline (SAS) and 1:1 (v:v) methanol:0.1 M ammonium acetate

(MAM) and allowed to dry. The SAS strips were cut at R_f 0.75 and the MAM strip

was cut at R_f 0.40. The portions of the strips were counted for radioactivity in a dose

calibrator, and the per cent activity of the top and bottom portions of each strip
calculated. The radiochemical purity of each sample was calculated as follows:

Purity by TLC = % bottom (SAS) - % bottom (MAM)

The radiochemical purity by TLC was ≥ 90%.

5

EXAMPLE 3

Formulated Kit Method for Radiolabeling with Technetium-99m

Formulated kits were prepared by combining components in an appropriate

10   ratio in aqueous solution, adjusting the pH to pH 7.4, dispensing 1.0 mL into glass
vials, and lyophilizing. The components were dissolved in aqueous solution such that
one milliliter (one vial) contained the following: 50 μg of the benzodiazepinedione
derivative of Example 1 with 25 mg sodium glucoheptonate dihydrate, 50 μg stannous
chloride dihydrate, 100 μg sodium edetate dihydrate, and 5 mg L-methionine. The

15   formulated kit was reconstituted with ^{99m}Tc-sodium pertechnetate (45 to 55 mCi) and
saline such that the total volume was 1.0 mL. Following reconstitution, the
formulated kit vials were incubated at 100°C in a boiling water bath for 10 minutes,
and allowed to cool for 20 minutes at room temperature.

The purity of the ^{99m}Tc-labeled benzodiazepinedione derivative was

20   determined by reverse-phase analytical HPLC using the following conditions: a
Zorbax 300SB C18, 4 μ, 4.6 mm x 250 mm analytical column was loaded with each
radiolabeled peptide, and the peptides eluted at a solvent flow rate equal to 1.2
mL/min. Gradient elution was performed using a linear gradient of 23-46% Solvent
D/Solvent C (Solvent C is 5 mM tetrabutylammonium phosphate pH 7.5 in water and

25   Solvent D is 5 mM tetrabutylammonium phosphate pH 7.5 in 60/40
acetonitrile/water) over 20 minutes; followed by a linear gradient of 46-100% Solvent
D/Solvent C over 5 minutes and 100% Solvent D/Solvent C for 5 minutes (Method 2).

Radioactive components were detected in HPLC Method 2 by the same
detection methods described for Method 1 in Example 2. The radiochemical purity

30   obtained from the formulated kit preparations (as determined by the % area of the
main ^{99m}Tc product peaks) was ≥ 90% for >6 hours.

The purity of the ^{99m}Tc-labeled benzodiazepinedione derivative was also
determined by TLC quality control analysis as described in Example 2.

Results of HPLC and TLC analysis of the ^{99m}Tc-labeled benzodiazepinedione

derivative synthesized in Example 1 are shown in Table 1.

Table 1

5   TLC and HPLC Results for ^{99m}Tc-Labeled Benzodiazepinedione

	TLC Purity (%)	HPLC Method	HPLC Retention Time (min)	HPLC Purity (%)
Example 2	99	1	10.8, 12.0	92
Example 3[a]	99	2	11.8, 13.7	94
	100	2	11.6, 13.5	94

[a]Two entries represent two different lots of formulated kits. .

10   **EXAMPLE 4**

                                  In vitro **Studies**

[99m]Tc-benzodiazepinedione derivative was prepared as described in Example

2.

Preparation of Platelet-Rich Plasma (PRP). In all experiments, platelets were

15   isolated on the day of the experiment from citrated human blood. After obtaining

informed consent, 27 mL of blood was withdrawn from the antecubital vein of healthy

adult volunteers into a polypropylene syringe containing 3 mL of sodium citrate

(3.8% w/v, pH 7.4). Universal precautions for handling biological fluids were

followed. Citrated blood was transferred to a 50 mL conical centrifuge tube and

20   centrifuged at 900 rpm (160xg) for 10 minutes to obtain PRP.

Washed Platelets. Washed platelets were prepared by centrifuging PRP at

2,200 rpm (1,400 x g) for 12 min. The platelet-poor plasma (PPP) was decanted and

the resulting pellet suspended in modified Tyrodes buffer. The PPP was decanted

and discarded. Modified Tyrodes buffer (0.8 mL per mL of original PRP) was

25   immediately layered over the platelet pellet and prostaglandin E_1 (PGE$_1$; 1 μL of a 40

μM solution per mL of Tyrodes buffer) added to prevent platelet activation. (McLane

MA, Kowalska MA, Silver L, Shattil SJ and Niewiarowski S. (1994) *Biochem J*

301: 429-426). The pellet was resuspended with a plastic Pasteur pipette. The

centrifugation step was repeated to wash the platelets that were diluted in 150 mL of Tyrodes buffer for binding assays.

Polyethyleneimine-Treated Filters. The filters (GF/C) were presoaked in 10 mM Tris-HCl (pH 9.1) polyethyleneimine (0.5%) and P829 (0.001%) for at least one
5   hour prior to assay to decrease the nonspecific binding of ^{99m}Tc labeled benzodiazepinedione derivative to the filter.

Binding of ^{99m}Tc-benzodiazepinedione derivative to Washed Platelets. Platelets (125 μL) were incubated in silanized glass tubes for 60 min at 37°C in a shaking water bath in a total volume of 250 μL of Tyrodes buffer containing ^{99m}Tc-
10   benzodiazepinedione derivative (50, 30, 10, 7, 5, 3, 1, 0.7, 0.5, 0.3, 0.1, and 0.07 nM final concentration). To determine the binding of ^{99m}Tc-benzodiazepinedione derivative to "activated" platelets, a 10 μL aliquot of a 0.5 mM solution of ADP (20 μM final concentration), and a 10 μL aliquot of a 1:1 mixture of 250 mM $CaCl_2$ and $MgCl_2$ was added to appropriate tubes. Nonspecific binding was determined by the
15   addition of excess unlabeled benzodiazepinedione derivative (100 μM) to fully saturate the GPIIb/IIIa receptor. The ^{99m}Tc-benzodiazepinedione derivative bound to the platelets was separated from the free ^{99m}Tc-benzodiazepinedione derivative by filtration through treated GF/C Glass Fiber Filters (Cat. No. FP24-GF/C, Brandel, Gaithersburg, MD) using a Brandel Cell harvester (Cat. No. SM24T Brandel,
20   Gaithersburg MD) connected to a vacuum source (15 to 20 mm Hg). Filters were then washed with 9 mL of 10 mM Tris-HCl buffer at pH 7.8 (4°C) and counted for radioactivity in a gamma counter.

Calculations. The specific binding of ^{99m}Tc-benzodiazepinedione derivative was calculated by subtracting the nonspecific binding in the presence of excess
25   unlabeled benzodiazepinedione derivative from the total binding measured in the absence of excess benzodiazepinedione derivative. The data were plotted as a Scatchard Plot as described in Bylung DB and Yamamura HI, *Methods for receptor binding*, Ravens Press Ltd. (New York. 1990) pp. 1-32. The data points were fitted with the linear regression function in the KaleidaGraph (Synergy Software Inc.)
30   software package. The K_d values were calculated as the negative reciprocal of the slope.

Statistics. Each response variable was compared between the two factor levels in each of the two factors using a paired student's t-test from the Instat Program (GraphPad Software, San Diego, CA). The threshold p value was set to 0.05 for rejection of the null hypothesis. For the Response Variable: K_d;   Level 1: Basal (no

5   ADP); Level 2: Activated (ADP), factor levels were compared in platelets isolated from the same individual. Experiments were run simultaneously. The platelets from four subjects were used.

The average K_d for the binding of ^{99m}Tc-benzodiazepinedione derivative to resting and activated human platelets was 30.5 nM and 13.5 nM, respectively. Thus,

10   more ^{99m}Tc-benzodiazepinedione derivative bound to activated platelets. The average fold-increase in binding to activated platelets over all concentrations tested was 1.8, and ranged from 1.2 to 2.3 fold. The data obtained from Scatchard plots from which the K_d values were derived are summarized in Table 2.

Table 2

15   Kd Values for Binding to Human Platelets (nM).

	Technetium Tc 99m P424	
	Basal	**ADP**
Subject 1	32	15
Subject 2	20	12
Subject 3	47	20
Subject 4	23	7
Mean	**30.5 ± 6**	**13.5 ± 3**

These data demonstrate that a ^{99m}Tc-benzodiazepinedione derivative produced in accordance with the invention binds with higher potency to activated platelets than

20   to resting platelets.

EXAMPLE 5

In Vivo Imaging of Deep Vein Thrombosis using a ^{99m}Tc-Labeled Benzodiazepinedione Derivative in a Canine Model

Three mongrel dogs (25-35lb., fasted overnight) were sedated with a

5   combination of ketamine and aceprozamine intramuscularly and then anesthetized with sodium pentabarbital intravenously. In each animal, an 18-gauge angiocath was inserted in the distal half of the right femoral vein and an 8mm Dacron®-entwined stainless steel embolization coil (Cook Co., Bloomington IN) was placed in the femoral vein at approximately mid-femur. The catheter was removed, the wound sutured and the

10 placement of the coil documented by X-ray. The animals were then allowed to recover overnight.

One day following coil placement, each animal was re-anesthetized, intravenous saline drips placed in each foreleg and a urinary bladder catheter inserted to collect urine. The animal was placed supine under a gamma camera which was equipped with a low-

15 energy, all purpose collimator and photopeaked for ^{99m}Tc.

The benzodiazepinedione derivative of Example 1 was labeled with ^{99m}Tc [185-370 mBq (5-10 mCi)] and injected sequentially into one foreleg intravenous line at its point of insertion. The second line was maintained for blood collection.

Gamma camera imaging was started simultaneously with injection. Anterior

20 images over the heart were acquired as a dynamic study (10 second image acquisitions) over the first 10 minutes, and then as static images at 1, 2, 3 and 4 hours post-injection. Anterior images over the legs were acquired for 500,000 counts or 20 minutes (whichever was shorter), at approximately 10-20 minutes, and at approximately 1, 2, 3 and 4 hours post-injection. Leg images were collected with a lead shield placed over the

25 bladder.

Following the final image, each animal was deeply anesthetized with pentobarbital. Two blood samples were collected on a cardiac puncture using a heparinized syringe followed by a euthanizing dose of saturated potassium chloride solution administered by intercardiac or bolus intravenous injection. The femoral vein

30 containing the thrombus, a similar section of vein of the contralateral (control) leg, sections of the vessel proximal to the thrombus and samples of thigh muscle were then carefully dissected out. The thrombus, coil and coil Dacron fibers were then dissected free of the vessel. The thrombus, saline-washed vessel samples, coil and coil Dacron

fibers were separated, and each sample was placed in a pre-weighed test tube. The samples were weighed and counted in a gamma well counter in the Tc-99m channel, along with known fractions of the injected doses.

Fresh thrombus weight, percent injected dose (%ID)/g in the thrombus and blood

5 obtained just prior to euthanasia and thrombus/blood and thrombus/muscle ratios were determined. From the computer-stored images, thrombus/background ratios were determined by analysis of the counts/pixel measured in regions-of-interest (ROI) drawn over the thrombus and adjacent muscle. Tissue data from these experiments are shown in Table 3.

10 **Table 3**

Canine Model of Pulmonary Embolism and Deep Vein Thrombosis[1]

	Leg Thrombus	Lung Thrombus
Thrombus/Background[2]	4.2 (n=2)	1.3 (n=1)
%ID/g Thrombus	0.050 ± 0.020	0.15 ± 0.048
Thrombus/Blood[3]	9.1 ± 4.6	27 ± 9
Thrombus/Muscle[3]	30 ± 15	--
Thrombus/Normal Lung[3]	--	29 ± 9
Thrombus Weight	430 ±210 mg	30 ± 15 mg

[1]Mean ± standard deviation
[2]From analysis of image regions of interest
15 [3]Ratio of % injected dose/g (%ID/g)

These results demonstrate that pulmonary emboli and deep vein thrombi can be rapidly and efficiently located *in vivo* using Tc-99m labeled benzodiazepinedione derivatives of the invention.

20 It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or equivalents thereto are within the spirit and scope of the invention as set forth in the appended claims.

33

CLAIMS

1.   A compound comprising a glycoprotein IIb/IIIa receptor binding benzodiazepine derivative covalently linked to a metal ion chelator, wherein the compound retains substantial potency for inhibition of human platelet aggregation, as measured in a standard inhibition of platelet aggregation assay.

2.   The compound of claim 1, having a formula:

where R^1 is C_1-C_8 lower alkyl, R^2, R^3, R^4, R^5, and R^6 are each independently H, C_1-C_8 lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

3.   The compound of claim 1, having a formula:

where R^2 is C_1-C_8 lower alkyl, R^1, R^3, R^4, R^5, and R^6 are each independently H, C_1-C_8 lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

4.   The compound of claim 1, having a formula:

where R^3 is C_1-C_8 lower alkyl; R^1, R^2, R^4, R^5, and R^6 are each independently H, C_1-C_8 lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a

5   linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

5.   The compound of claim 1, having a formula:

10   where R^4 is C_1-C_8 lower alkyl; R^1, R^2, R^3, R^5, and R^6 are each independently H, C_1-C_8 lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

6, The compound of claim 1, having a formula:

where R^5 is C_1-C_8 lower alkyl; R^1,R^2, R^3, R^4, and R^6 are each independently H, C_1-C_8
lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a
linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a
metal ion chelator.

7.   The compound of claim 1, having a formula:

where R^6 is C_1-C_8 lower alkyl; R^1,R^2, R^3, R^4, and R^5 are each independently H, C_1-C_8
lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a
linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a
metal ion chelator.

8.   The compound of claim 1, wherein the chelator comprises a single
thiol-containing group.

9.   The compound of claim 8, wherein the single thiol-containing group has
a formula:

$$A\text{--}CZ(B)\text{--}\{C(R^aR^b)\}_n\text{--}X$$

wherein A is H, HOOC–, H_2NOC–, –NHOC–, –OOC–, R^e_2NOC–, or R^d; B is H, SH,

–NHR^c, –N(R^c)– or R^d; Z is H or R^d; X is SH, –NHR^c, –N(R^c)– or R^d; R^a, R^b, R^c and R^d are independently H, straight chain C$_1$-C$_8$ alkyl, branched chain C$_1$-C$_8$ alkyl, or cyclic C$_3$-C$_8$ alkyl; n is 0, 1 or 2; R^c is C$_1$-C$_4$ alkyl, an amino acid, or a peptide comprising 2 to about 10 amino acids; and: (1) where B is –NHR^c or –N(R^c)–, X is SH and n is 1 or 2; (2) where X is –NHR^c or –N(R^c)–, B is SH and n is 1 or 2; (3) where B is H or R^d, A is HOOC–, H$_2$NOC–, –NHOC–, or –OOC–, X is SH and n is 0 or 1; (4) where A is H or R^d, then where B is SH, X is –NHR^c or –N(R^c)– and where X is SH, B is –NHR^c or –N(R^c)– and n is 1 or 2; (5) where X is H or R^d, A is HOOC–, H$_2$NOC–, –NHOC–, or –OOC– and B is SH; (6) where Z is methyl, X is methyl, A is HOOC–, H$_2$NOC–, –NHOC–, or –OOC– and B is SH and n is 0; and (7) where B is SH, X is not SH and where X is SH, B is not SH.

10.   A compound having a formula:

wherein M is a metal ion chelator.

11.   The compound of claim 10, wherein M is selected from the group consisting of:

a)

R^1-CO-(amino acid)^1-(amino acid)^2-Z^1

wherein (amino acid)^1 and (amino acid)^2 are each independently any primary α- or β-amino acid that does not comprise a thiol group, Z^1 is selected from the group consisting of cysteine, homocysteine, isocysteine, penicillamine, 2-mercaptoethylamine, 2-

mercaptopropylamine, 2-mercapto-2-methylpropylamine, and 3-mercaptopropylamine, and R^1 is lower (C^1-C^4) alkyl, or R^1-CO is an amino acid, a peptide, or (aa)-peptide; wherein when Z^1 is cysteine, homocysteine, isocysteine or penicillamine, Z^1 comprises a carbonyl group covalently linked to a hydroxyl group, a NR^3R^4 group, wherein each of

5   R^3 and R^4 are independently H, a bond, lower (C^1-C^4) alkyl, an amino acid or a peptide comprising from 2 to 10 amino acids; and

        b)

$$Y\text{-(amino acid)}^2\text{-(amino acid)}^1\text{-}NHR^2$$

wherein (amino acid)^1 and (amino acid)^2 are each independently any primary α- or β-

10   amino acid that does not comprise a thiol group Y is selected from the group consisting of cysteine, homocysteine, isocysteine, penicillamine, 2-mercaptoacetate, 2-mercaptopropionate, 2-mercapto-2-methylpropionate, 3-mercaptopropionate, and R^2 is H, a bond, lower (C^1-C^4) alkyl, and NHR^2 is an amino acid, a peptide, or (aa)-peptide; wherein when Y is cysteine, homocysteine, isocysteine or penicillamine, Y comprises an

15   amino group covalently linked to –H, an amino acid, a peptide, or (aa)-peptide.

        12. The compound of claim 10, wherein M is selected from the group consisting of:
        –Gly–Gly–Cys, –Gly–Gly–Cys.amide, Gly–Gly–Cys–, Cys–Gly–Gly–,

20   –Gly–Gly–Gly–Cys (SEQ ID NO: 1), –Gly–Gly–Gly–Cys.amide (SEQ ID NO:1), Arg–Gly–Cys–, –(ε-Lys)–Gly–Cys–, –(δ-Orn)–Gly–Cys–, –(γ-Dab)–Gly–Cys–, and –(β-Dap)–Lys–Cys–

        13. The compound of claim 10, wherein M is –Gly–Gly–Gly–Cys.amide (SEQ

25   ID NO:1).

        14. A pharmaceutical composition comprising 1-[(carboxyglycyl-glycyl-glycyl-cysteinamide)methyl]-4-(2-carboxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione trifluoroacetate.

30

        15. The composition of claim 14, further comprising ^{99m}Tc.

16. A scintigraphic imaging agent comprising a γ-emitting radionuclide and a compound comprising a glycoprotein IIb/IIIa receptor binding benzodiazepine covalently linked to a metal ion chelating moiety, wherein the compound retains substantial potency for inhibition of human platelet aggregation, as measured in a

5   standard inhibition of platelet aggregation assay.

17. The agent of claim 16, wherein the radionuclide is ^{99m}Tc.

18. A complex of a γ-emitting radionuclide and a compound comprising a

10   glycoprotein IIb/IIIa receptor binding benzodiazepine covalently linked to a metal ion chelating moiety, wherein the compound retains substantial potency for inhibition of human platelet aggregation, as measured in a standard inhibition of platelet aggregation assay.

15   19. The complex of claim 18, wherein the radionuclide is ^{99m}Tc.

20. A ^{99m}Tc chelate of a compound comprising a glycoprotein IIb/IIIa receptor binding benzodiazepine covalently linked to a metal ion chelating moiety, wherein:

20   a) the compound retains substantial potency for inhibition of human platelet aggregation, as measured in a standard inhibition of platelet aggregation assay; and

         b) the chelate contains at least one sulfur ligand bound to ^{99m}Tc.

21. A method of detecting a thrombus in a mammalian body, comprising the

25   steps of administering an effective diagnostic amount of the composition of claim 15 to the body and detecting radiation localized at the thrombus.

22. A method of detecting a thrombus in a mammalian body, comprising the steps of administering an effective diagnostic amount of the agent of claim 17 to the

30   body and detecting radiation localized at the thrombus.

23. A method of detecting a thrombus in a mammalian body, comprising the steps of administering an effective diagnostic amount of the complex of claim 19 to the body and detecting radiation localized at the thrombus.

5   24. A method of detecting a thrombus in a mammalian body, comprising the steps of administering an effective diagnostic amount of the chelate of claim 20 to the body and detecting radiation localized at the thrombus.

        25. A kit comprising a sealed vial containing:

10   a) a predetermined quantity of 1-[(carboxyglycyl-glycyl-glycyl-cysteinamide)methyl]-4-(2-carboxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione trifluoroacetate; and

        b) a reducing agent.

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K51/04   C07D243/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols) IPC 7   A61K   C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BIOSIS, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 08174 A (GENENTECH INC.) 29 April 1993 (1993-04-29) cited in the application claims 2-6,10-15 & US 5 403 836 A 4 April 1995 (1995-04-04) cited in the application ---	1-25
Y	US 5 879 657 A (W. F. DEGRADO ET AL) 9 March 1999 (1999-03-09) claims 1,25-50 --- -/--	1-25

[X] Further documents are listed in the continuation of box C.   [X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
3 August 2000	11/08/2000

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl; Fax: (+31–70) 340–3016	Authorized officer Siatou, E

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	SHUANG LIU ET AL: "LABELING CYCLIC GLYCOPROTEIN IIB/IIIA RECEPTOR ANTAGONISTS WITH 99MTC BY THE PREFORMED CHELATE APPROACH: EFFECTS OF CHELATORS ON PROPERTIES OF U99MTCCHELATOR-PEPTIDE CONJUGATES" BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 7, no. 2, 1 March 1996 (1996-03-01), pages 196-202, XP000558420 ISSN: 1043-1802 abstract page 199; figure 2	1-25
A	BARRETT J A ET AL: "BIOLOGICAL EVALUATION OF 99MTC-LABELED CYCLIC GLYCOPROTEIN IIB/IIIARECEPTOR ANTAGONISTS IN THE CANINE ARTERIOVENOUS SHUNG AND DEEP VEIN THROMBOSIS MODELS: EFFECTS OF CHELATORS ON BIOLOGICAL PROPERTIES OF U99MTCCHELATOR-PEPTIDE CONJUGATES" BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 7, no. 2, 1 March 1996 (1996-03-01), pages 203-208, XP000558421 ISSN: 1043-1802 abstract page 203; figure 1	1-25
A	LIU S ET AL: "LABELING A HYDRAZINO NICOTINAMIDE-MODIFIED CYCLIC IIB/IIIA RECEPTORANTAGONIST WITH 99MTC USING AMINOCARBOXYLATES AS COLIGANDS" BIOCONJUGATE CHEMISTRY, vol. 7, 1996, pages 63-71, XP002050942 abstract	1-25
A	PEARSON D A ET AL: "THROMBUS IMAGING USING TECHNETIUM-99M-LABELED HIGH-POTENCY GPIIB/IIIA RECEPTOR ANTAGONISTS. CHEMISTRY AND INITIAL BIOLOGICAL STUDIES" JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 39, no. 7, 1996, pages 1372-1382, XP002061485 ISSN: 0022-2623 abstract	1-25

-/--

2

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	RAJOPADHYE M ET AL: "Synthesis, evaluation and Tc-99m complexation of a hydrazinonicotinyl conjugate of a gp IIb/IIIa antagonist cyclic peptide for the detection of deep vein thrombosis" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 8, 22 April 1997 (1997-04-22), pages 955-960, XP004136163 ISSN: 0960-894X the whole document	1-25
A	KU T W ET AL: "DIRECT DESIGN OF A POTENT NON-PEPTIDE FIBRINOGEN RECEPTOR ANTAGONIST BASED ON THE STRUCTURE AND CONFORMATION OF A HIGHLY CONSTRAINED CYCLIC RGD PEPTIDE" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, vol. 115, 1993, pages 8861-8862, XP000196275 ISSN: 0002-7863 cited in the application the whole document	1-25
A	US 5 830 856 A (R. T DEAN ET AL) 3 November 1998 (1998-11-03) cited in the application claims 1-22	1-25
A	US 5 645 815 A (R. T. DEAN ET AL) 8 July 1997 (1997-07-08) cited in the application claims 1-25	1-25

2

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9308174	A	29-04-1993	US	5250679 A	05-10-1993
			AT	133412 T	15-02-1996
			AU	673501 B	14-11-1996
			AU	2797692 A	21-05-1993
			CA	2119745 A	29-04-1993
			DE	69207916 D	07-03-1996
			DE	69207916 T	17-10-1996
			DK	610334 T	03-06-1996
			EP	0610334 A	17-08-1994
			ES	2085651 T	01-06-1996
			FI	941222 A	02-06-1994
			GR	3019517 T	31-07-1996
			JP	7500341 T	12-01-1995
			NO	941378 A	20-06-1994
			US	5403836 A	04-04-1995
			US	5674865 A	07-10-1997
			US	5674863 A	07-10-1997
			US	5663166 A	02-09-1997
			US	5565449 A	15-10-1996
US 5879657	A	09-03-1999	AT	194293 T	15-07-2000
			AU	689643 B	02-04-1998
			AU	3452595 A	21-03-1996
			AU	6524894 A	24-10-1994
			BG	100036 A	29-11-1996
			BR	9406055 A	10-09-1996
			BR	9406820 A	10-09-1996
			CA	2159445 A	13-10-1994
			CN	1122577 A	15-05-1996
			EP	0692982 A	24-01-1996
			EP	0995761 A	26-04-2000
			FI	954655 A	02-11-1995
			HU	72889 A	28-06-1996
			JP	3042887 B	22-05-2000
			JP	8509710 T	15-10-1996
			LV	11106 A	20-04-1996
			LV	11106 B	20-04-1997
			NO	953886 A	30-11-1995
			NZ	263970 A	25-09-1996
			PL	311037 A	22-01-1996
			US	6010679 A	04-01-2000
			WO	9422494 A	13-10-1994
			US	5744120 A	28-04-1998
			US	5750088 A	12-05-1998
			US	6015904 A	18-01-2000
			US	6022523 A	08-02-2000
			RO	114895 A	30-08-1999
			ZA	9402262 A	02-10-1995
US 5830856	A	03-11-1998	AU	709306 B	26-08-1999
			AU	2764295 A	04-01-1996
			CA	2191949 A	14-12-1995
			EP	0772460 A	14-05-1997
			JP	10501236 T	03-02-1998
			WO	9533496 A	14-12-1995
			US	6022520 A	08-02-2000
			ZA	9504549 A	26-02-1996
			AU	687080 B	19-02-1998

Form PCT/ISA/210 (patent family annex) (July 1992)

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5830856	A		AU	7241394 A	08-11-1994
			CA	2160120 A	27-10-1994
			EP	0693941 A	31-01-1996
			JP	2954355 B	27-09-1999
			JP	8508999 T	24-09-1996
			SG	49788 A	15-06-1998
			WO	9423758 A	27-10-1994
			US	5645815 A	08-07-1997
			US	6056940 A	02-05-2000
			US	5997845 A	07-12-1999
			ZA	9402439 A	08-01-1996
			AT	188387 T	15-01-2000
			AU	658617 B	27-04-1995
			AU	1411792 A	07-09-1992
			CA	2101942 A	09-08-1992
			DE	69230525 D	10-02-2000
			DE	69230525 T	21-06-2000
			EP	0570493 A	24-11-1993
			ES	2141102 T	16-03-2000
			JP	2774378 B	09-07-1998
			JP	6503352 T	14-04-1994
			US	5552525 A	03-09-1996
			US	5561220 A	01-10-1996
			WO	9213572 A	20-08-1992
			US	5997844 A	07-12-1999
			US	5654272 A	05-08-1997
			US	5849260 A	15-12-1998
			US	5849261 A	15-12-1998
			US	5714579 A	03-02-1998
			US	5788960 A	04-08-1998
			US	5681541 A	28-10-1997
			US	5879658 A	09-03-1999
			US	5888474 A	30-03-1999
			US	5811394 A	22-09-1998
			US	5736122 A	07-04-1998
			US	6019958 A	01-02-2000
			US	6074627 A	13-06-2000
US 5645815	A	08-07-1997	US	6056940 A	02-05-2000
			US	5997845 A	07-12-1999
			AU	687080 B	19-02-1998
			AU	7241394 A	08-11-1994
			CA	2160120 A	27-10-1994
			EP	0693941 A	31-01-1996
			JP	2954355 B	27-09-1999
			JP	8508999 T	24-09-1996
			SG	49788 A	15-06-1998
			WO	9423758 A	27-10-1994
			US	6022520 A	08-02-2000
			US	5830856 A	03-11-1998
			ZA	9402439 A	08-01-1996
			AT	188387 T	15-01-2000
			AU	658617 B	27-04-1995
			AU	1411792 A	07-09-1992
			CA	2101942 A	09-08-1992
			DE	69230525 D	10-02-2000
			DE	69230525 T	21-06-2000
			EP	0570493 A	24-11-1993

Form PCT/ISA/210 (patent family annex) (July 1992)

International Application No

PCT/US 00/10093

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5645815 A		ES 2141102 T	16-03-2000
		JP 2774378 B	09-07-1998
		JP 6503352 T	14-04-1994
		US 5552525 A	03-09-1996
		US 5561220 A	01-10-1996
		WO 9213572 ·A	20-08-1992
		US 5997844 A	07-12-1999
		US 5654272 A	05-08-1997
		US 5849260 A	15-12-1998
		US 5849261 A	15-12-1998
		US 5714579 A	03-02-1998
		US 5788960 A	04-08-1998
		US 5681541 A	28-10-1997
		US 5879658 A	09-03-1999
		US 5888474 A	30-03-1999
		US 5811394 A	22-09-1998
		US 5736122 A	07-04-1998
		US 6019958 A	01-02-2000
		US 6074627 A	13-06-2000